Well-known companies including Pfizer, Allergan and GlaxoSmithKline put up the price of their medicines on January 1 in a move that will lead to higher bills for patients. Now some investors are asking whether politicians might pursue regulations to curb the practice.

► Subscribe to FT.com here: http://bit.ly/2r8RJzM

► Subscribe to the Financial Times on YouTube: http://bit.ly/FTimeSubs

For more video content from the Financial Times, visit http://www.FT.com/video


Twitter https://twitter.com/ftvideo
Facebook https://www.facebook.com/financialtimes